Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
- PMID: 11016644
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
Abstract
Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar compounds that induce growth arrest in transformed cells and show promise for the treatment of cancer. SAHA induces differentiation and/or apoptosis in certain transformed cells in culture and is a potent inhibitor of histone deacetylases. In this study, we examined the effects of SAHA on the growth of human prostate cancer cells in culture and on the growth of the CWR22 human prostate xenograft in nude mice. SAHA suppressed the growth of the LNCaP, PC-3, and TSU-Pr1 cell lines at micromolar concentrations (2.5-7.5 microM). SAHA induced dose-dependent cell death in the LNCaP cells. In mice with transplanted CWR222 human prostate tumors, SAHA (25, 50, and 100 mg/kg/day) caused significant suppression of tumor growth compared with mice receiving vehicle alone; treatment with 50 mg/kg/day resulted in a 97% reduction in the mean final tumor volume compared with controls. At this dose, there was no detectable toxicity as evaluated by weight gain and necropsy examination. Increased accumulation of acetylated core histones was detected in the CWR22 tumors within 6 h of SAHA administration. SAHA induced prostate-specific antigen mRNA expression in CWR22 prostate cancer cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.
Similar articles
-
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.Clin Cancer Res. 2007 Feb 1;13(3):1045-52. doi: 10.1158/1078-0432.CCR-06-1261. Clin Cancer Res. 2007. PMID: 17289901
-
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14. Cancer Chemother Pharmacol. 2010. PMID: 20838997
-
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.BMC Cancer. 2006 Jul 11;6:183. doi: 10.1186/1471-2407-6-183. BMC Cancer. 2006. PMID: 16834771 Free PMC article.
-
Histone deacetylase inhibitors as new cancer drugs.Curr Opin Oncol. 2001 Nov;13(6):477-83. doi: 10.1097/00001622-200111000-00010. Curr Opin Oncol. 2001. PMID: 11673688 Review.
-
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6. doi: 10.1093/jnci/92.15.1210. J Natl Cancer Inst. 2000. PMID: 10922406 Review.
Cited by
-
Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage.Genes Cancer. 2015 Jan;6(1-2):49-61. doi: 10.18632/genesandcancer.52. Genes Cancer. 2015. PMID: 25821561 Free PMC article.
-
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.Neurooncol Adv. 2020 Jul 3;2(1):vdaa084. doi: 10.1093/noajnl/vdaa084. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 32793886 Free PMC article.
-
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.Neuro Oncol. 2007 Apr;9(2):82-8. doi: 10.1215/15228517-2006-032. Epub 2007 Mar 8. Neuro Oncol. 2007. PMID: 17347490 Free PMC article.
-
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8. doi: 10.1073/pnas.191208598. Epub 2001 Sep 4. Proc Natl Acad Sci U S A. 2001. PMID: 11535817 Free PMC article.
-
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.J Clin Pathol. 2007 Nov;60(11):1205-10. doi: 10.1136/jcp.2005.029165. Epub 2007 Aug 24. J Clin Pathol. 2007. PMID: 17720775 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical